title: Treatment of primary liver graft non-function with prostaglandin E1 results in increased graft and patient survival.
authors.affiliation: Liver Transplant Program, University of Toronto, Ontario, Canada.
authors.forename: P D
authors.initials: PD
authors.lastname: Greig
authors.forename: G M
authors.initials: GM
authors.lastname: Woolf
authors.forename: M
authors.initials: M
authors.lastname: Abecassis
authors.forename: S M
authors.initials: SM
authors.lastname: Strasberg
authors.forename: B
authors.initials: B
authors.lastname: Taylor
authors.forename: R A
authors.initials: RA
authors.lastname: Superina
authors.forename: B
authors.initials: B
authors.lastname: Langer
authors.forename: M F
authors.initials: MF
authors.lastname: Glynn
authors.forename: M
authors.initials: M
authors.lastname: Ettles
authors.forename: L
authors.initials: L
authors.lastname: Blendis
mesh_terms: D000328:Adult; D000527:Alprostadil / Q000008:administration & dosage / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001777:Blood Coagulation / Q000187:drug effects; D002405:Catheterization, Central Venous; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006085:Graft Survival / Q000187:drug effects*; D006801:Humans; D007262:Infusions, Intravenous; D008099:Liver / Q000187:drug effects / Q000503:physiopathology; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D001219:Aspartate Aminotransferases; D000527:Alprostadil